12. Phosphodiesterase Inhibitors in Obstructive Lung Disease

  1. Jan Lötvall
  1. Jan Lötvall2 and
  2. Bo Lundbäck1

Published Online: 29 FEB 2012

DOI: 10.1002/9781119998624.ch12

Advances in Combination Therapy for Asthma and COPD

Advances in Combination Therapy for Asthma and COPD

How to Cite

Lötvall, J. and Lundbäck, B. (2012) Phosphodiesterase Inhibitors in Obstructive Lung Disease, in Advances in Combination Therapy for Asthma and COPD (ed J. Lötvall), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781119998624.ch12

Editor Information

  1. Krefting Research Centre, University of Gothenburg, Göteborg, Sweden

Author Information

  1. 1

    Krefting Research Centre, University of Gothenburg, Sweden

  2. 2

    Krefting Research Centre, University of Gothenburg, Göteborg, Sweden

Publication History

  1. Published Online: 29 FEB 2012
  2. Published Print: 3 FEB 2012

ISBN Information

Print ISBN: 9780470727027

Online ISBN: 9781119998624

SEARCH

Keywords:

  • obstructive lung disease;
  • phosphodiesterase enzymes;
  • pharmacological agents, blocking PDE4;
  • PDE4 inhibition, biological effects;
  • PDE4 inhibition in COPD;
  • PDE4 inhibitors, and side effects;
  • obstructive airways disease

Summary

This chapter contains sections titled:

  • Introduction

  • Phosphodiesterase enzymes

  • Different pharmacological agents blocking PDE4

  • Biological effects of PDE4 inhibition, preclinical information

  • Clinical effects of PDE4 inhibition in COPD

  • Effects of PDE4 inhibitors on systemic processes in COPD

  • Side effects of PDE4 inhibitors

  • PDE4 inhibitors in COPD management plans

  • Future prospects with PDE4 inhibitors in obstructive airways disease

  • Summary

  • References